Patrick R. O’neil Sells 1000 Shares of ISIS Pharmaceuticals, Inc. (ISIS) Stock – Dakota Financial News

Patrick R. O’neil Sells 1000 Shares of ISIS Pharmaceuticals, Inc. (ISIS) StockDakota Financial NewsThe Company is focused to discover and develop antisense drugs. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer. ISIS-APOCIII is a …and more »

Read More

Cellmid granted midkine patent – NT News

Cellmid granted midkine patentNT NewsTHE patent is a part of its inhibitor patent portfolio and includes MK antibodies, antisense RNA and dsRNA against MK. The patent forms the basis for the commercial development of its MK antibodies in autoimmune disease indications. Increase Text Size …and more »

Read More

Research reveals MECP2 Duplication Syndrome can be reversed

The methyl CpG binding protein 2 gene (MECP2) produces a protein of the same name, the level of which is critical for normal brain function. Mutations leading to protein under-expression cause Rett Syndrome while gene duplication causing over-expression lead to MECP2 Duplication Syndrome. Both disorders are severely debilitating childhood neurological diseases.

Read More

MECP2 duplication syndrome is reversible – EurekAlert (press release)

MECP2 duplication syndrome is reversibleEurekAlert (press release)Importantly the study paves the way for treating duplication patients with an antisense oligonucleotide strategy. The research, funded in part by the MECP2 Duplication Syndrome Fund at the Rett Syndrome Research Trust (RSRT), was made possible through …Normalizing levels of MeCP2 in mouse model of MECP2 duplication syndrome …Medical Xpressall 6 news articles »

Read More

Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules … – FierceBiotech

Boston Business JournalIdera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules …FierceBiotechThis collaboration broadens the utility of our third generation antisense platform beyond the stated areas of focus for Idera in cancers and rare diseases,” stated Clayton Fletcher, Idera’s Senior Vice President of Business Development and Strategic …GSK, Idera Partner on Third-Gen Antisense Drugs for Renal DiseaseGenetic Engineering & Biotechnology News (blog)all 20 news articles »

Read More

GSK, Idera Partner on Third-Gen Antisense Drugs for Renal Disease – Genetic Engineering & Biotechnology News (blog)

Boston Business JournalGSK, Idera Partner on Third-Gen Antisense Drugs for Renal DiseaseGenetic Engineering & Biotechnology News (blog)GlaxoSmithKline (GSK) will partner with Idera Pharmaceuticals to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform against targets in renal disease. The deal, announced today by Idera, could …Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules …FierceBiotechIdera Pharma (IDRA), Glaxo (GSK) Enter Antisense Development, License AgreementStreetInsider.comall 26 news articles »

Read More

Insider Sale: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s SVP – Antisense … – OctaFinance.com

STORMInsider Sale: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s SVP – Antisense …OctaFinance.comThe SVP – Antisense Research of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) 62.77 +0.73 1.18% and corporation’s insider Frank Bennett unloaded 5,000 shares of the -listed Isis Pharmaceuticals Inc based on the stock price per share of $64.0 of a share.Joseph Klein Unloaded $441234 Worth of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS …FinancialMagazin.comInsider Selling: C Frank Bennett Sells 5000 Shares of ISIS Pharmaceuticals …Voice ChronicleISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS)Dakota Financial NewsMidSouth Newz -STORMall 13 news articles »

Read More

ISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS) – Dakota Financial News

STORMISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS)Dakota Financial NewsThe Firm is focused to discover and develop antisense drugs. The antisense drugs are utilized to deal with a range of diseases, including cardiovascular, infrequent, serious and metabolic diseases. ISIS-APOCIII is a drug demonstrated to to treat …Insider Selling: C Frank Bennett Sells 5000 Shares of ISIS Pharmaceuticals …Voice ChronicleNeedham & Company LLC Lowers ISIS Pharmaceuticals Price Target to $88.00 (ISIS)STORMall 9 news articles »

Read More

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

Read More

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) SVP – Antisense Research Frank … – FinancialMagazin.com

The San Diego Union-TribuneISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) SVP – Antisense Research Frank …FinancialMagazin.comIn consideration of sell Frank Bennett made he is in the insider trading spotlight today. The SVP – Antisense Research of Isis Pharmaceuticals Inc and an insider, made a sale of 5,000 shares worth $280,000 USD. The average price was $56.0 per share.Isis Pharma jumps 12 percentThe San Diego Union-TribuneWhy Isis Pharmaceuticals Is More Potent TodayMotley FoolISIS Pharmaceuticals Price Target Raised to $65.00 at Barclays (ISIS)Dakota Financial NewsZacks.com -PR Newswire (press release) -Voice Chronicleall 42 news articles »

Read More

Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients … – PR Newswire (press release)

Phys.OrgIsis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients …PR Newswire (press release)Isis is primarily responsible for drug discovery and early development of antisense therapies. Biogen has the option to license each antisense program at a particular stage in development. Current development-stage programs include antisense drugs to …Company Update (NASDAQ:ISIS): ISIS Pharmaceuticals, Inc. Earns $2.8M for …Smarter AnalystCurrent Trade Stocks Recap: Southwest Airlines Co (NYSE:LUV), ISIS …wsnewspublishersall 11 news articles »

Read More

Isis Pharma jumps 12 percent – The San Diego Union-Tribune

The San Diego Union-TribuneIsis Pharma jumps 12 percentThe San Diego Union-TribuneThe company says it is progressively refining antisense to make it more potent, and this will be reflected in newer generations of drugs. Volansorsen and ISIS-APO(a)Rx are considered advanced second-generation antisense drugs. None of the antisense …Why Isis Pharmaceuticals Is More Potent TodayMotley FoolIsis Pharmaceuticals (ISIS) Q3 Loss Narrower than ExpectedZacks.comIsis Reports Financial Results and Highlights for Third Quarter 2015PR Newswire (press release)Street Report -Nasdaqall 42 news articles »

Read More

Global Antisense and RNAi Therapeutics Market 2015 Clinical Trails, Research … – Medgadget.com (blog)

Medgadget.com (blog)Global Antisense and RNAi Therapeutics Market 2015 Clinical Trails, Research …Medgadget.com (blog)Global Antisense and RNAi Therapeutics Market 2015-2019Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which …

Read More

Isis Pharmaceuticals Inc (NASDAQ:ISIS) Institutional Investors Sentiment Index … – FinancialMagazin.com

StreetWise ReportIsis Pharmaceuticals Inc (NASDAQ:ISIS) Institutional Investors Sentiment Index …FinancialMagazin.comThe Firm is focused to discover and develop antisense drugs. It has 275.02 P/E ratio. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer.Isis Pharma begins phase 2 study of ISIS-FXI Rx in patients with ESRD on …pharmabiz.comIsis starts phase 2 study of ISIS-FXIRx drugPharmaceutical Business Reviewall 5 news articles »

Read More

Emerging Biotechnologies -Antisense RNAi Therapeutics Industry 2015 Global … – Medgadget.com (blog)

Medgadget.com (blog)Emerging Biotechnologies -Antisense RNAi Therapeutics Industry 2015 Global …Medgadget.com (blog)2. Global Emerging Biotechnologies -Antisense RNAi Therapeutics Industry 2015 Review, Research, Size, Share, Industry Analysis, Trends and Forecast 2025 3. This report provides top line data relating to the clinical trials 4. Report includes an …and more »

Read More